This site is intended for healthcare professionals
News

FDA accepts sNDA for Recarbrio in hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.- Merck Inc

Read time: 1 mins
Published:4th Feb 2020
Merck Inc announced that the FDA has accepted for review a supplemental New Drug Application (sNDA) for Recarbrio (imipenem, cilastatin, and relebactam) to treat adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by certain susceptible Gram-negative microorganisms. The application has received Priority Review by the FDA, and the Prescription Drug User Fee Act (PDUFA) date for the sNDA is June 4, 2020. The submission is based on the results of the pivotal Phase III RESTORE-IMI 2 trial in adult patients with HABP/VABP. The full data has been accepted for presentation at the 30th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2020), which will take place in Paris, France, April 18 – 21, 2020.Recabrio was initially approved by the FDA in July 2019 for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, and complicated intra-abdominal infections (cIAI) caused by susceptible Gram-negative bacteria, in adults who have limited or no alternative treatment options.
Condition: Infectious Diseases/HABP/VABP
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.